Mizuho lowered the firm’s price target on Alector to $9 from $10 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q3 results. The firm notes the shares are trading below cash and at a negative enterprise value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALEC:
- Alector to Participate in the Stifel Healthcare Conference
- Alector reports Q3 EPS (53c), consensus (66c)
- Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
- Alector achieves target enrollment in INFRONT-3 Phase 3 trial of latozinemab
- Alector initiated with a Sell at Goldman Sachs